Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

The methylprednisolone sodium succinate

Phase 3Small molecule

TTang-Du Hospital

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Endovascular ThrombectomyRecruiting

Endovascular ThrombectomyPhase 3

Recruiting

Timeline

Expected Milestones

Q2 2028

Phase 3Recruiting

Endovascular Thrombectomy

NCT07141303

Clinical

Trials by Indication[1]

Endovascular Thrombectomy1 trial

Intra-arterial Methylprednisolone After Successful Endovascular Thrombectomy Anterior Circulation Large Vessel Occlusion

Recruiting·TTang-Du Hospital·Phase 3·NCT07141303·1,060 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for The methylprednisolone sodium succinate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — The methylprednisolone sodium succinate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for The methylprednisolone sodium succinate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tang-Du Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTang-Du Hospital

Related News